Concord Healthcare unveils AI-driven proton therapy model
BEIJING, May 30, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that Concord Healthcare had made important progress in precise tumor diagnosis and treatment technology. Concord Healthcare's self-developed large language model ("LLM") in the vertical field of proton therapy was officially released and successfully deployed in Guangzhou Concord Cancer Hospital. Since the commencement of the proton therapy in Guangzhou Concord Cancer Hospital, the proton therapy has completed a number of high-quality patient treatment cases, demonstrating the outstanding advantages of precise treatment, significant efficacy, and reduced side effects.
Concord Healthcare's proton LLM is the first LLM focusing on proton therapy in China, and its research and development relies on the tumor diagnosis and treatment technology system and massive data accumulated by Concord Healthcare over the years. It integrates nearly 10,000 high-quality radiotherapy cases to construct multimodal medical data, and also integrates data from Proton China and professional journal literature to achieve enhancement of model training.
The Company previously announced the listing of Concord Healthcare's H shares on the HKSE on January 9, 2024. The information related to Concord Healthcare's Transactions on the HKSE is accessible through the HKSE's website at www.hkexnews.hk.
What the stars mean:
★ Poor ★ ★ Promising ★★★ Good ★★★★ Very good ★★★★★ Exceptional
Tag:
Latest News
Mobile Version